HuH-7人肝癌细胞

HuH7/HuH7细胞系/HuH7细胞株/HuH7人肝癌细胞

Cell line name Huh-7

Synonyms HuH-7; HUH-7; HuH7; Huh7; HUH7; HUH7.0; JTC-39; Japanese Tissue Culture-39

Accession CVCL_0336

Resource Identification Initiative To cite this cell line use: Huh-7 (RRID:CVCL_0336)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: ENCODE project common cell types; tier 3.

Part of: JFCR45 cancer cell line panel.

Part of: Liver Cancer Model Repository (LIMORE).

Part of: MD Anderson Cell Lines Project.

Part of: TCGA-110-CL cell line panel.

Population: Japanese.

Doubling time: 22 +- 1 hours (PubMed=11152498); 32.2 hours (PubMed=31378681); ~48 hours (CLS=300156).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced.

Omics: miRNA expression profiling.

Omics: Mitochondrial proteome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Liver; UBERON=UBERON_0002107.

Source(s): CCRID; CLS=300156; Cosmic-CLP=907071; JCRB=JCRB0403; KCLB=60104; PubMed=25877200; PubMed=29774518; PubMed=31378681; RCB=RCB1366; Technion Genomics Center; TKG=TKG 0206

 

Markers:

Amelogenin X

CSF1PO 11

D1S1656 16

D2S441 12,14

D2S1338 19

D3S1358 15

D5S818 12

D6S1043 13,15

D7S820 11

D8S1179 14,15

D10S1248 16

D12S391 20 (CLS=300156; Technion Genomics Center)

20,21 (CCRID)

D13S317 10 (CLS=300156; RCB=RCB1366; Technion Genomics Center)

10,11 (CCRID; Cosmic-CLP=907071; JCRB=JCRB0403; KCLB=60104; PubMed=25877200; PubMed=29774518; PubMed=31378681; TKG=TKG 0206)

D16S539 10

D18S51 15

D19S433 13,14

D21S11 30

D22S1045 17,20

FGA 22,23

Penta D 12

Penta E 11

TH01 7

TPOX 8,11

vWA 16,18 (CCRID; Cosmic-CLP=907071; JCRB=JCRB0403; KCLB=60104; PubMed=25877200; PubMed=29774518; PubMed=31378681; RCB=RCB1366; TKG=TKG 0206)

18 (CLS=300156; Technion Genomics Center)

PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613

Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J.-W., Ozturk M.

Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.

FASEB J. 7:1407-1413(1993)

 

PubMed=8389256; DOI=10.1093/carcin/14.5.987

Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.

p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.

Carcinogenesis 14:987-992(1993)

 

PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A

Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-i., Teruya K., Kosaka T., Tsuji T., Namba M.

Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.

J. Med. Virol. 48:133-140(1996)

 

DOI=10.11418/jtca1981.16.3_173

Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ohashi R., Namba M.

The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.

Tissue Cult. Res. Commun. 16:173-178(1997)

 

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

 

PubMed=9359923; DOI=10.18926/AMO/30789

Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ishioka C., Namba M.

Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.

Acta Med. Okayama 51:261-265(1997)

 

PubMed=10523694; DOI=10.3892/or.6.6.1267

Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.

Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.

Oncol. Rep. 6:1267-1271(1999)

 

PubMed=11152498; DOI=10.1128/JVI.75.3.1252-1264.2001; PMCID=PMC114031

Pietschmann T., Lohmann V., Rutter G., Kurpanek K., Bartenschlager R.F.W.

Characterization of cell lines carrying self-replicating hepatitis C virus RNAs.

J. Virol. 75:1252-1264(2001)

 

PubMed=12029633; DOI=10.1053/jhep.2002.33683

Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.

TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Hepatology 35:1476-1484(2002)

 

PubMed=15708988; DOI=10.1128/JVI.79.5.2689-2699.2005; PMCID=PMC548482

Sumpter R.M. Jr., Loo Y.-M., Foy E.M., Li K., Yoneyama M., Fujita T., Lemon S.M., Gale M. Jr.

Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I.

J. Virol. 79:2689-2699(2005)

 

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234

Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Mol. Cancer Ther. 4:399-412(2005)

 

PubMed=16935386; DOI=10.1016/j.jhep.2006.05.019

Sun D.-X., Nassal M.

Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus.

J. Hepatol. 45:636-645(2006)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)